Our study suggests that RanGAP1 downregulation by miR-1301 or other methods is a novel beneficial strategy for enhancing IM efficacy in CML patients. This evidence concerns the gene RANGAP1 and chronic myelogenous leukemia, BCR-ABL1 positive.